Merck and Seattle Genetics announced a new collaboration on a treatment for cancer, a deal that includes Merck buying $1 billion in Seattle Genetics shares, sending SGEN stock soaring.

The post Seattle Genetics Pact With Drug Giant Merck Sends SGEN Stock Soaring appeared first on Investor's Business Daily.